Our targeted approach focuses on indications where Notch-pathway activation is a known tumorigenic driver. Using our deep understanding of the Notch pathway, we are developing targeted therapies to address the underlying key drivers of tumor growth in patients where GSI inhibition of Notch may lead to clinical benefit.
With possibly the largest database of Notch-activating mutations to inform our efforts, we know that the Notch mutational landscape is diverse in specific cancers that can benefit from a modern screening tool. We have developed a proprietary bioinformatics platform to analyze next-generation sequencing data and identify patients in whom Notch is a tumorigenic driver and therefore may benefit from GSI treatment. We apply our big-data analysis capabilities to identify and confirm patients with Notch-activating mutations who are likely sensitive to GSIs.
Our scientists utilize unique capabilities in bioinformatics and functional biology to create a Notch-focused patient identification engine that we believe will result in the discovery of additional patients with currently undetected Notch-activating mutations.
Progressing Desmoid Tumors
Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC)
Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (R/R T-ALL)
Our scientists utilize unique capabilities in bioinformatics and functional biology to create a Notch-focused patient identification engine that we believe will result in the discovery of additional patients with currently undetected Notch-activating mutations.
Progressing Desmoid Tumors
Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC)
Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (R/R T-ALL)
Our scientists utilize unique capabilities in bioinformatics and functional biology to create a Notch-focused patient identification engine that we believe will result in the discovery of additional patients with currently undetected Notch-activating mutations.
Progressing Desmoid Tumors
Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC)
Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (R/R T-ALL)